European Union - English - EMA (European Medicines Agency)

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - combinations - clopidogrel/acetylsalicylic acid teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (asa). clopidogrel/acetylsalicylic acid teva is a fixed‑dose combination medicinal product for continuation of therapy in:non‑st segment elevation acute coronary syndrome (unstable angina or non‑q‑wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionst segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - ibandronic acid - wounds and injuries; breast diseases; neoplastic processes; calcium metabolism disorders; water-electrolyte imbalance - drugs for treatment of bone diseases - ibandronic acid is indicated in adults forprevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.treatment of tumour induced hypercalcaemia with or without metastases.treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1).a reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone - drugs for treatment of bone diseases, bisphosphonates - ibandronic acid sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.,

European Union - English - EMA (European Medicines Agency)

teva pharma b.v. - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone; osteoporosis, postmenopausal - drugs for treatment of bone diseases - ibandronic acid 50mgibandronic acid teva is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.ibandronic acid 150mgtreatment of osteoporosis in postmenopausal women at increased risk of fracture. a reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.

European Union - English - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic acid - xanthomatosis, cerebrotendinous; metabolism, inborn errors - bile and liver therapy - chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (ctx)) in infants, children and adolescents aged 1 month to 18 years and adults.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - hydrogen peroxide; peroxyacetic acid - soluble concentrate - hydrogen peroxide ungrouped active 299.0 g/l; peroxyacetic acid acid-general active 50.0 g/l - disinfectant

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - phosphoric acid; sulphamic acid; sulphuric acid (98%) - soluble concentrate - phosphoric acid mineral-phosphorus-acid active 149.0 g/l; sulphamic acid mineral-sulfur-acid active 23.0 g/l; sulphuric acid (98%) mineral-sulfur-acid active 126.0 g/l - dairy cleanser

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fusidic acid 20.35 mg/g (as the 0.5 hydrate) - topical cream - 20 mg/g - active: fusidic acid 20.35 mg/g (as the 0.5 hydrate) excipient: butylated hydroxyanisole cetyl alcohol glycerol hydrochloric acid liquid paraffin polysorbate 60 potassium sorbate purified water white soft paraffin - indicated either alone or in combination with systemic therapy, in the treatment of primary and secondary skin infections caused by sensitive strains of staphylococcus aureus, streptococcus spp and corynebacterium minutissimum. primary skin infections that may be expected to respond to treatment with fusidic acid applied topically include: impetigo contagiosa, superficial folliculitis, sycosis barbae, paronychia and erythrasma; also such secondary skin infections as infected eczematoid dermatitis, infected contact dermatitis and infected cuts/abrasions.

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - tranexamic acid 100 mg/ml;   - solution for injection - 500 mg/5ml - active: tranexamic acid 100 mg/ml   excipient: hydrochloric acid sodium hydroxide water for injection - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. local fibrinolysis may occur in the following conditions: - prostatectomy and bladder surgery - menorrhagia - epistaxis - conisation of the cervix - management of dental extraction in patients with coagulopathies - ulcerative colitis - haematuria (tranexamic acid therapy is not indicated in haematuria caused by diseases of the renal parenchyma (also see precautions). - gastrointestinal haemorrhage.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule - excipient ingredients: titanium dioxide; maize starch; silicon dioxide; gelatin; magnesium stearate - ursodeoxycholic acid is indicated in the treatment of chronic cholestatic liver diseases.